354 related articles for article (PubMed ID: 33225764)
1. Considerations when treating high-grade pediatric glioma patients with immunotherapy.
Crotty E; Downey K; Ferrerosa L; Flores C; Hegde B; Raskin S; Hwang E; Vitanza N; Okada H
Expert Rev Neurother; 2021 Feb; 21(2):205-219. PubMed ID: 33225764
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
Lu VM; Alvi MA; McDonald KL; Daniels DJ
J Neurosurg Pediatr; 2018 Nov; 23(3):308-316. PubMed ID: 30544362
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy approaches for the treatment of diffuse midline gliomas.
Bernstock JD; Hoffman SE; Kappel AD; Valdes PA; Essayed W; Klinger NV; Kang KD; Totsch SK; Olsen HE; Schlappi CW; Filipski K; Gessler FA; Baird L; Filbin MG; Hashizume R; Becher OJ; Friedman GK
Oncoimmunology; 2022; 11(1):2124058. PubMed ID: 36185807
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development.
Garcia-Fabiani MB; Ventosa M; Comba A; Candolfi M; Nicola Candia AJ; Alghamri MS; Kadiyala P; Carney S; Faisal SM; Schwendeman A; Moon JJ; Scheetz L; Lahann J; Mauser A; Lowenstein PR; Castro MG
Expert Opin Investig Drugs; 2020 Jul; 29(7):659-684. PubMed ID: 32400216
[TBL] [Abstract][Full Text] [Related]
7. Cutting Edge Therapeutic Insights Derived from Molecular Biology of Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG).
Bailey CP; Figueroa M; Mohiuddin S; Zaky W; Chandra J
Bioengineering (Basel); 2018 Oct; 5(4):. PubMed ID: 30340362
[TBL] [Abstract][Full Text] [Related]
8. Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models.
Martinez-Velez N; Marigil M; García-Moure M; Gonzalez-Huarriz M; Aristu JJ; Ramos-García LI; Tejada S; Díez-Valle R; Patiño-García A; Becher OJ; Gomez-Manzano C; Fueyo J; Alonso MM
Acta Neuropathol Commun; 2019 Apr; 7(1):64. PubMed ID: 31036068
[TBL] [Abstract][Full Text] [Related]
9. Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities.
Haase S; Nuñez FM; Gauss JC; Thompson S; Brumley E; Lowenstein P; Castro MG
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348922
[TBL] [Abstract][Full Text] [Related]
10. Pediatric high-grade glioma: moving toward subtype-specific multimodal therapy.
Chatwin HV; Cruz Cruz J; Green AL
FEBS J; 2021 Nov; 288(21):6127-6141. PubMed ID: 33523591
[TBL] [Abstract][Full Text] [Related]
11. The genetic signatures of pediatric high-grade glioma: no longer a one-act play.
Diaz AK; Baker SJ
Semin Radiat Oncol; 2014 Oct; 24(4):240-7. PubMed ID: 25219808
[TBL] [Abstract][Full Text] [Related]
12. Single vs. combination immunotherapeutic strategies for glioma.
Chandran M; Candolfi M; Shah D; Mineharu Y; Yadav VN; Koschmann C; Asad AS; Lowenstein PR; Castro MG
Expert Opin Biol Ther; 2017 May; 17(5):543-554. PubMed ID: 28286975
[TBL] [Abstract][Full Text] [Related]
13. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas.
Lasky JL; Panosyan EH; Plant A; Davidson T; Yong WH; Prins RM; Liau LM; Moore TB
Anticancer Res; 2013 May; 33(5):2047-56. PubMed ID: 23645755
[TBL] [Abstract][Full Text] [Related]
14. Pediatric hemispheric high-grade glioma: targeting the future.
Coleman C; Stoller S; Grotzer M; Stucklin AG; Nazarian J; Mueller S
Cancer Metastasis Rev; 2020 Mar; 39(1):245-260. PubMed ID: 31989507
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic virus therapy for malignant gliomas: entering the new era.
Fudaba H; Wakimoto H
Expert Opin Biol Ther; 2023 Mar; 23(3):269-282. PubMed ID: 36809883
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy in brain tumors].
De Carli E; Delion M; Rousseau A
Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
[TBL] [Abstract][Full Text] [Related]
17. Novel chemotherapeutics and other therapies for treating high-grade glioma.
Kang JH; Adamson C
Expert Opin Investig Drugs; 2015; 24(10):1361-79. PubMed ID: 26289791
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success.
Hervás-Corpión I; Alonso MM
Int Rev Cell Mol Biol; 2023; 379():169-188. PubMed ID: 37541723
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell therapy of high-grade gliomas.
Van Gool S; Maes W; Ardon H; Verschuere T; Van Cauter S; De Vleeschouwer S
Brain Pathol; 2009 Oct; 19(4):694-712. PubMed ID: 19744041
[TBL] [Abstract][Full Text] [Related]
20. Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas.
Fangusaro J
J Child Neurol; 2009 Nov; 24(11):1409-17. PubMed ID: 19638636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
